Erman Akkus: Is adjuvant Gem-Cis better than capecitabine in operated node-positive extrahepatic cholangiocarcinoma?

Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter:

“Is adjuvant Gem-Cis better than capecitabine in operated node-positive extrahepatic cholangiocarcinoma? STAMP trial: Not a negative study.

• 101 patients
• 31.7% had R1 resection
• 2-year disease-free survival: 38.5% vs 25.1% (HR=0.96 (CI, 0.71–1.30), p=0.430)
• median overall survival: 35.7 mo (29.5–NE) vs 35.7 months (30.9–NE) [HR=1.08 (CI, 0.71–1.64), 1-sided p=0.404)
• Grade 3–4 AE: 84% vs 16%”

Read further.
Source: Erman Akkus/X